Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37113745/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: Initial evidence from our real-world clinical setting suggests that semaglutide may be effective in reducing AAWG in patients not responding to metformin. Randomized control trials investigating semaglutide for AAWG are needed to corroborate these findings.
Share
Semaglutide-eye-catching results
Source : https://www.wjgnet.com/1948-9358/full/v14/i4/424.htm
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a class of drugs increasingly used for the treatment of patients with type 2 diabetes mellitus (T2DM), enhancing glucose management while promoting weight loss...
Core Tip: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit patients with type 2 diabetes mellitus in terms of glucose management, weight control, oxidative damage, and prevention of adverse renal and cardiovascular events without increasing the of risk of hypoglycemia. After reviewing the literature to investigate upon such a...
Share
Combination Therapy of Metformin and p-Coumaric Acid Mitigates Metabolic Dysfunction Associated with Obesity and Non-Alcoholic Fatty Liver Disease in High-Fat Diet Obese C57BL/6 Mice
Source : https://www.sciencedirect.com/science/article/abs/pii/S095528632300102X?via=ihub
Available online 25 April 2023, 109369 Author links open overlay panel, , , , Reza Meshkani 1 Show more Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic...
Conclusions/Relevance: Taken together, these findings indicate that MET combined with PCA can improve NAFLD through decreasing lipid accumulation, inhibiting inflammation and inducing thermogenesis, and adipose tissue browning.
Share
Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37088648/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents.
Share
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37086147/
The role of stimulating glucagon receptors in the treatment of type 2 diabetes and/or obesity is poorly defined and needs to be clarified. Although retatrutide may be superior to the...
Expert Opinion: The role of stimulating glucagon receptors in the treatment of type 2 diabetes and/or obesity is poorly defined and needs to be clarified. Although retatrutide may be superior to the GLP-1 receptor agonist dulaglutide in reducing plasma glucose and body weight, this is not a meaningful comparison, as another GLP-1 receptor...
Share